Blockbusters Drugs Account for a Third of Global Pharmaceutical Sales; URCH Report Highlights Reliance Big Pharma Has on Billion Dollar Sellers.LONDON London, city, Canada London, city (1991 pop. 303,165), SE Ont., Canada, on the Thames River. The site was chosen in 1792 by Governor Simcoe to be the capital of Upper Canada, but York was made capital instead. London was settled in 1826. -- PHARMACEUTICAL PRODUCTS with sales of more than US$1 billion a year account for more than one third of the total market for pharmaceuticals, highlights a new report from URCH Publishing. "Pharmaceutical Market Trends, 2006-2010: Key market forecasts and growth opportunities" identifies 100 drugs classed as blockbusters which account for 34 percent of the pharmaceutical market by value. The top seller was Lipitor Lip·i·tor A trademark for the drug atorvastatin calcium. atorvastatin calcium Lipitor Pharmacologic class: HMG-CoA reductase inhibitor Therapeutic class: a cholesterol-lowering medication marketed by Pfizer Pfizer Incorporated (NYSE: PFE) is a major research-based pharmaceutical company, which ranks number two in sales The company is based in New York City. It produces the number-one selling drug Lipitor (atorvastatin, used to lower blood cholesterol); the oral antifungal with sales of US$12,187 million, while the fastest growing drug last year was another cholesterol treatment Vytorin, co-marketed by Merck and Schering-Plough, which saw a 678% increase in sales to pass the billion dollar mark. A total of 14 blockbusters had falling sales in 2005, but this was countered by 16 products that achieved blockbuster block·bust·er n. 1. Something, such as a film or book, that sustains widespread popularity and achieves enormous sales. 2. A high-explosive bomb used for demolition purposes. 3. status. The largest pharmaceutical corporations have become increasingly reliant on mega-selling brands to deliver profits, however they are in a potentially exposed position should revenue substantially fall. For example, last year saw sales of Pfizer's osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. treatment Celebrex Cel·e·brex A trademark for the drug celecoxib. celecoxib Celebrex Pharmacologic class: Nonsteroidal cyclooxygenase-2 (COX-2) inhibitor, nonsteroidal anti-inflammatory drug (NSAID) fall by 47 percent over safety concerns after the highly publicised Adj. 1. publicised - made known; especially made widely known publicized withdrawal of Merck's Vioxx Vi·oxx A trademark for the drug rofecoxib. Vioxx® Rofecoxib Pain management A COX-2 inhibitor used to manage osteoarthritic pain, acute pain in adults, primary dysmenorrhea. See COX-2 inhibitor. . Pfizer products generated 14 percent of blockbuster sales and accounted for 63 percent of the firm's sales, says the 170 page report. Blockbusters are dominated by more mature products, those that have been approved for marketing for between five and ten years. "Blockbuster sales continue to be dominated by traditional drugs, with therapeutic biologics accounting for just 17.2% of total blockbuster sales revenue in 2005" said Steve Seget, the report's author. The report methodology provides a detailed but transparent analysis of key pharmaceutical market trends, including key markets, therapy areas, products and companies. Historical trends are formed over a three-year time horizon and future forecasts are made using a five-year future time period. Thus, the data and analysis relate to the eight-year time horizon from 2003 to 2010. "Pharmaceutical Market Trends, 2006-2010: Key market forecasts and growth opportunities" is available from URCH Publishing. Find more details at http://www.urchpublishing.com/publications/general/pharma_trends_00 About URCH Publishing Ltd URCH Publishing Ltd is an independent business information publisher dedicated to delivering quality information products to the global pharmaceuticals industry. Press review copies may be available on request. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion